Investor Relations

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Stock Market
NASDAQSNGX
Featured Presentation

Soligenix Corporate Presentation

 

October 3, 2024

Dr. Brian Poligone, Clinical Investigator for CTCL Phase 3 FLASH Study, Answers Questions About Patient Care and Treatment Options

Read the Transcript

Latest News
Oct 22, 2024
Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis PRINCETON, N.J., Oct. 22, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

Oct 16, 2024
Soligenix Invited to Present at Upcoming Investor Conferences

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet...

Oct 7, 2024
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

Two Presentations Highlight HyBryte™ Therapy's Improved Response Rates with Extended Treatment and Increased Light Doses PRINCETON, N.J., Oct. 7, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq:...

All Press Releases

IR Contacts

29 Emmons Drive
Suite B-10 Princeton, NJ 08540
Telephone: 609-538-8200
ir@soligenix.com

Subscribe For Alerts

If you would like to receive our Investor Relations updates, please sign up for email alerts. 

 

 

Sign Up